Literature DB >> 25561462

HDL from apoA1 transgenic mice expressing the 4WF isoform is resistant to oxidative loss of function.

Stela Z Berisha1, Greg Brubaker1, Takhar Kasumov2, Kimberly T Hung1, Patricia M DiBello1, Ying Huang1, Ling Li3, Belinda Willard3, Katherine A Pollard4, Laura E Nagy4, Stanley L Hazen5, Jonathan D Smith5.   

Abstract

HDL functions are impaired by myeloperoxidase (MPO), which selectively targets and oxidizes human apoA1. We previously found that the 4WF isoform of human apoA1, in which the four tryptophan residues are substituted with phenylalanine, is resistant to MPO-mediated loss of function. The purpose of this study was to generate 4WF apoA1 transgenic mice and compare functional properties of the 4WF and wild-type human apoA1 isoforms in vivo. Male mice had significantly higher plasma apoA1 levels than females for both isoforms of human apoA1, attributed to different production rates. With matched plasma apoA1 levels, 4WF transgenics had a trend for slightly less HDL-cholesterol versus human apoA1 transgenics. While 4WF transgenics had 31% less reverse cholesterol transport (RCT) to the plasma compartment, equivalent RCT to the liver and feces was observed. Plasma from both strains had similar ability to accept cholesterol and facilitate ex vivo cholesterol efflux from macrophages. Furthermore, we observed that 4WF transgenic HDL was partially (∼50%) protected from MPO-mediated loss of function while human apoA1 transgenic HDL lost all ABCA1-dependent cholesterol acceptor activity. In conclusion, the structure and function of HDL from 4WF transgenic mice was not different than HDL derived from human apoA1 transgenic mice.
Copyright © 2015 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  ATP binding cassette transporter A1; apolipoprotein A1; cholesterol efflux; dysfunctional high density lipoprotein; myeloperoxidase; reverse cholesterol transport

Mesh:

Substances:

Year:  2015        PMID: 25561462      PMCID: PMC4340312          DOI: 10.1194/jlr.M056754

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  50 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT.

Authors:  Ian Tietjen; G Kees Hovingh; Roshni Singaraja; Chris Radomski; Jason McEwen; Elden Chan; Maryanne Mattice; Annick Legendre; John J P Kastelein; Michael R Hayden
Journal:  Biochim Biophys Acta       Date:  2011-08-19

Review 3.  Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials.

Authors:  Erin D Michos; Christopher T Sibley; Jefferson T Baer; Michael J Blaha; Roger S Blumenthal
Journal:  J Am Coll Cardiol       Date:  2012-04-18       Impact factor: 24.094

4.  Zymosan-mediated inflammation impairs in vivo reverse cholesterol transport.

Authors:  Priya Malik; Stela Z Berisha; Jennifer Santore; Colin Agatisa-Boyle; Gregory Brubaker; Jonathan D Smith
Journal:  J Lipid Res       Date:  2011-02-19       Impact factor: 5.922

5.  Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks.

Authors:  Xin-Min Li; Wai Hong Wilson Tang; Marian K Mosior; Ying Huang; Yuping Wu; William Matter; Vivian Gao; David Schmitt; Joseph A Didonato; Edward A Fisher; Jonathan D Smith; Stanley L Hazen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-03-21       Impact factor: 8.311

Review 6.  High-density lipoprotein function, dysfunction, and reverse cholesterol transport.

Authors:  Edward A Fisher; Jonathan E Feig; Bernd Hewing; Stanley L Hazen; Jonathan D Smith
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-12       Impact factor: 8.311

7.  Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Authors:  Gregory G Schwartz; Anders G Olsson; Markus Abt; Christie M Ballantyne; Philip J Barter; Jochen Brumm; Bernard R Chaitman; Ingar M Holme; David Kallend; Lawrence A Leiter; Eran Leitersdorf; John J V McMurray; Hardi Mundl; Stephen J Nicholls; Prediman K Shah; Jean-Claude Tardif; R Scott Wright
Journal:  N Engl J Med       Date:  2012-11-05       Impact factor: 91.245

8.  Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export.

Authors:  Baohai Shao; Chongren Tang; Jay W Heinecke; John F Oram
Journal:  J Lipid Res       Date:  2010-01-11       Impact factor: 5.922

9.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study.

Authors:  Benjamin F Voight; Gina M Peloso; Marju Orho-Melander; Ruth Frikke-Schmidt; Maja Barbalic; Majken K Jensen; George Hindy; Hilma Hólm; Eric L Ding; Toby Johnson; Heribert Schunkert; Nilesh J Samani; Robert Clarke; Jemma C Hopewell; John F Thompson; Mingyao Li; Gudmar Thorleifsson; Christopher Newton-Cheh; Kiran Musunuru; James P Pirruccello; Danish Saleheen; Li Chen; Alexandre F R Stewart; Arne Schillert; Unnur Thorsteinsdottir; Gudmundur Thorgeirsson; Sonia Anand; James C Engert; Thomas Morgan; John Spertus; Monika Stoll; Klaus Berger; Nicola Martinelli; Domenico Girelli; Pascal P McKeown; Christopher C Patterson; Stephen E Epstein; Joseph Devaney; Mary-Susan Burnett; Vincent Mooser; Samuli Ripatti; Ida Surakka; Markku S Nieminen; Juha Sinisalo; Marja-Liisa Lokki; Markus Perola; Aki Havulinna; Ulf de Faire; Bruna Gigante; Erik Ingelsson; Tanja Zeller; Philipp Wild; Paul I W de Bakker; Olaf H Klungel; Anke-Hilse Maitland-van der Zee; Bas J M Peters; Anthonius de Boer; Diederick E Grobbee; Pieter W Kamphuisen; Vera H M Deneer; Clara C Elbers; N Charlotte Onland-Moret; Marten H Hofker; Cisca Wijmenga; W M Monique Verschuren; Jolanda M A Boer; Yvonne T van der Schouw; Asif Rasheed; Philippe Frossard; Serkalem Demissie; Cristen Willer; Ron Do; Jose M Ordovas; Gonçalo R Abecasis; Michael Boehnke; Karen L Mohlke; Mark J Daly; Candace Guiducci; Noël P Burtt; Aarti Surti; Elena Gonzalez; Shaun Purcell; Stacey Gabriel; Jaume Marrugat; John Peden; Jeanette Erdmann; Patrick Diemert; Christina Willenborg; Inke R König; Marcus Fischer; Christian Hengstenberg; Andreas Ziegler; Ian Buysschaert; Diether Lambrechts; Frans Van de Werf; Keith A Fox; Nour Eddine El Mokhtari; Diana Rubin; Jürgen Schrezenmeir; Stefan Schreiber; Arne Schäfer; John Danesh; Stefan Blankenberg; Robert Roberts; Ruth McPherson; Hugh Watkins; Alistair S Hall; Kim Overvad; Eric Rimm; Eric Boerwinkle; Anne Tybjaerg-Hansen; L Adrienne Cupples; Muredach P Reilly; Olle Melander; Pier M Mannucci; Diego Ardissino; David Siscovick; Roberto Elosua; Kari Stefansson; Christopher J O'Donnell; Veikko Salomaa; Daniel J Rader; Leena Peltonen; Stephen M Schwartz; David Altshuler; Sekar Kathiresan
Journal:  Lancet       Date:  2012-05-17       Impact factor: 79.321

10.  HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.

Authors: 
Journal:  Eur Heart J       Date:  2013-02-26       Impact factor: 29.983

View more
  6 in total

1.  Methionine oxidized apolipoprotein A-I at the crossroads of HDL biogenesis and amyloid formation.

Authors:  Andrzej Witkowski; Gary K L Chan; Jennifer C Boatz; Nancy J Li; Ayuka P Inoue; Jaclyn C Wong; Patrick C A van der Wel; Giorgio Cavigiolio
Journal:  FASEB J       Date:  2018-01-17       Impact factor: 5.191

2.  Efficient Site-Specific Prokaryotic and Eukaryotic Incorporation of Halotyrosine Amino Acids into Proteins.

Authors:  Hyo Sang Jang; Xiaodong Gu; Richard B Cooley; Joseph J Porter; Rachel L Henson; Taylor Willi; Joseph A DiDonato; Stanley L Hazen; Ryan A Mehl
Journal:  ACS Chem Biol       Date:  2020-02-10       Impact factor: 5.100

3.  PI(4,5)P2 Is Translocated by ABCA1 to the Cell Surface Where It Mediates Apolipoprotein A1 Binding and Nascent HDL Assembly.

Authors:  Kailash Gulshan; Gregory Brubaker; Heather Conger; Shuhui Wang; Renliang Zhang; Stanley L Hazen; Jonathan D Smith
Journal:  Circ Res       Date:  2016-08-11       Impact factor: 17.367

4.  Oxidant resistant human apolipoprotein A-I functions similarly to the unmodified human isoform in delaying atherosclerosis progression and promoting atherosclerosis regression in hyperlipidemic mice.

Authors:  Emmanuel Opoku; Stela Berisha; Gregory Brubaker; Peggy Robinet; Jonathan D Smith
Journal:  PLoS One       Date:  2022-02-04       Impact factor: 3.240

5.  Stent-based delivery of AAV2 vectors encoding oxidation-resistant apoA1.

Authors:  Bahman Hooshdaran; Benjamin B Pressly; Ivan S Alferiev; Jonathan D Smith; Philip W Zoltick; Cory M Tschabrunn; Robert L Wilensky; Robert C Gorman; Robert J Levy; Ilia Fishbein
Journal:  Sci Rep       Date:  2022-03-31       Impact factor: 4.996

Review 6.  Understanding Myeloperoxidase-Induced Damage to HDL Structure and Function in the Vessel Wall: Implications for HDL-Based Therapies.

Authors:  Gunther Marsche; Julia T Stadler; Julia Kargl; Michael Holzer
Journal:  Antioxidants (Basel)       Date:  2022-03-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.